Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against IntelliPharmaCeutics International Inc. (''IntelliPharmaCeutics'' or the ''Company'') (NASDAQ: IPCI) for possible violations of federal securities laws from January 14, 2016 through July 26, 2017, inclusive (the ''Class Period''). Investors who purchased or otherwise acquired IntelliPharmaCeutics shares during the Class Period should contact the firm before the September 29, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint alleges that throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its Rexista New Drug Application (''NDA''); that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting sufficient data to support approval of the NDA; and that as a result of the above, the Company's statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. Following the release of this news, IntelliPharmaCeutics' stock price fell materially, which caused investors harm.

Lundin Law PC was established by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 475361

"/> SHAREHOLDER REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm « MarketersMedia – Press Release Distribution Services – News Release Distribution Services

SHAREHOLDER REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against IntelliPharmaCeutics International Inc. and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 13, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against IntelliPharmaCeutics International Inc. (''IntelliPharmaCeutics'' or the ''Company'') (NASDAQ: IPCI) for possible violations of federal securities laws from January 14, 2016 through July 26, 2017, inclusive (the ''Class Period''). Investors who purchased or otherwise acquired IntelliPharmaCeutics shares during the Class Period should contact the firm before the September 29, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint alleges that throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its Rexista New Drug Application (''NDA''); that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting sufficient data to support approval of the NDA; and that as a result of the above, the Company's statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. Following the release of this news, IntelliPharmaCeutics' stock price fell materially, which caused investors harm.

Lundin Law PC was established by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 475361

LOS ANGELES, CA / ACCESSWIRE / September 13, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against IntelliPharmaCeutics International Inc. (''IntelliPharmaCeutics'' or the ''Company'') (NASDAQ: IPCI) for possible violations of federal securities laws from January 14, 2016 through July 26, 2017, inclusive (the ''Class Period''). Investors who purchased or otherwise acquired IntelliPharmaCeutics shares during the Class Period should contact the firm before the September 29, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

The Complaint alleges that throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its Rexista New Drug Application (''NDA''); that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting sufficient data to support approval of the NDA; and that as a result of the above, the Company's statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. Following the release of this news, IntelliPharmaCeutics' stock price fell materially, which caused investors harm.

Lundin Law PC was established by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 475361

Source URL: https://marketersmedia.com/shareholder-reminder-lundin-law-pc-announces-securities-class-action-lawsuit-against-intellipharmaceutics-international-inc-and-reminds-investors-with-losses-to-contact-the-firm/239044

Source: AccessWire

Release ID: 239044


Latest News